Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation

Natalie Lowry, Fiona Cowden, Edward Day, Eilish Gilvarry, Stacey Johnstone, Robbie Murray, Mike Kelleher, Luke Mitcheson, John Marsden

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Introduction: Opioid use disorder (OUD) is a debilitating and persistent disorder. The standard-of-care treatment is daily maintenance dosing of sublingual buprenorphine (BUP-SL) or oral methadone (MET). Monthly, extended-release, subcutaneous injectable buprenorphine (BUP-XR) has been developed to enhance treatment effectiveness. This study aims to investigate the experiences of participants who have been offered BUP-XR (evaluation 1), health-related quality-of-life among participants who have opted to receive BUP-XR longer term (evaluation 2) and the experiences of participants allocated to receive BUP-XR or BUP-SL or MET with the offer of adjunctive personalised psychosocial intervention (evaluation 3).

    Methods and analysis: Three qualitative-quantitative (mixed-methods) evaluations embedded in a five-centre, head-to-head, randomised controlled trial of BUP-XR versus BUP-SL and MET in the UK. Evaluation 1 is a four-centre interview anchored on an OUD-related topic guide and conducted after the 24-week trial endpoint. Evaluation 2 is a two-centre interview anchored on medications for opioid use disorder-specific quality-of-life topic guide conducted among participants after 12-24 months. Evaluation 3: single-centre interview after the 24-week trial endpoint. All evaluations include selected trial clinical measures, with evaluation 2 incorporating additional questionnaires. Target participant recruitment for evaluations 1 and 2 is 15 participants per centre (n=60 and n=30, respectively). Recruitment for evaluation 3 is 15 participants per treatment arm (n=30). Each evaluation will be underpinned by theory, drawing on constructs from the behavioural model for health service use or the health-related quality-of-life model. Qualitative data analysis will be by iterative categorisation.

    Ethics and dissemination: Study protocol, consent materials and questionnaires were approved by the London-Brighton and Sussex research ethics committee (reference: 19/LO/0483) and the Health Research Authority (IRAS project number 255522). Participants will be provided with information sheets and informed written consent will be obtained for each evaluation. Study findings will be disseminated through peer-reviewed scientific journals.

    Trial registration number: 2018-004460-63.

    Original languageEnglish
    Article numbere067194
    Number of pages7
    JournalBMJ Open
    Volume12
    Issue number10
    DOIs
    Publication statusPublished - 21 Oct 2022

    Keywords

    • Humans
    • Buprenorphine/therapeutic use
    • Methadone/therapeutic use
    • Narcotic Antagonists/therapeutic use
    • Opioid-Related Disorders/drug therapy
    • Tablets/therapeutic use
    • Randomized Controlled Trials as Topic
    • substance misuse
    • clinical trials
    • qualitative research

    Fingerprint

    Dive into the research topics of 'Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation'. Together they form a unique fingerprint.

    Cite this